Revolutionizing BPH Treatment: Profound Medical Corp. Introduces TULSA-AI® Volume Reduction Module
Profound Medical Corp., a medical device company specializing in AI-powered, MRI-guided therapies for treating diseased tissue, has announced the upcoming launch of its TULSA-AI® Volume Reduction module for patients with benign prostatic hyperplasia (BPH) at the RSNA meeting in Chicago. BPH is a common condition in aging men that causes an enlargement of the prostate gland, leading to urinary flow issues and lower urinary tract symptoms.
The current standard treatment for BPH, transurethral resection of the prostate (TURP), has remained largely unchanged for the past century. To address the limitations and complications associated with traditional treatments, Profound Medical Corp. has developed the TULSA-AI® Volume Reduction module, which aims to optimize the treatment of BPH patients by providing a more effective and less invasive alternative.
By leveraging AI technology and MRI guidance, the TULSA-AI® Volume Reduction module offers a non-invasive approach to treating BPH, reducing the risk of complications such as bleeding, erectile dysfunction, and the need for extended hospital stays. This innovative solution represents a significant advancement in the field of prostate treatment, offering patients a more efficient and comfortable experience.
Profound Medical Corp.'s commitment to developing cutting-edge medical technologies underscores its dedication to improving patient outcomes and revolutionizing the treatment of various medical conditions. The launch of the TULSA-AI® Volume Reduction module at the RSNA meeting marks a milestone in the company's mission to provide innovative solutions for patients with BPH and other related conditions.